Glycemic ControlInsulin therapy

Clinical evidence dossier

Insulin therapy

Glucose iAUC (OGTT)

Evidence signal

Authoritative evidence signal

strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
3
Reported effects
9

Clinical conclusion

Insulin therapy shows a moderate positive evidence signal for improving Glucose iAUC (OGTT) across the studied comparisons.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Mean difference

-21.01 to 18.58 %

2 eligible estimates12–12 weeksObserved median: -1.2150000000000016 %

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
2

Consistency

Authoritative consistency classification

mostly_consistent

Positive
2
No effect
0
Mixed
0
Negative
1

Population and applicability

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 2 studies described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Participants using hybrid closed-loop insulin therapy.
  • Elderly patients aged 65 and older with type 2 diabetes.
  • Patients requiring insulin therapy for diabetes management.
  • Adults diagnosed with type 2 diabetes
  • Patients currently on premixed insulin therapy

Limitations

  • 1 of 2 studies with duration data have follow-up of 12 weeks or less.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence